Figure 2.
PFS by cytogenetic risk status. Cytogenetic risk was assessed via nextgeneration sequencing. High-risk patients had any of t(4;14), t(14;16), or del17p. Standard-risk patients had an absence of high-risk abnormalities. PFS: progression- free survival; D-Rd: daratumumab/lenalidomide/dexamethasone; Rd: lenalidomide/dexamethasone; HR: hazard ratio; CI: confidence interval